Mexico Breast Cancer Drugs Market Size & Outlook, 2023-2030
Mexico breast cancer drugs, 2018-2030 (US$M)
Related Markets
Mexico breast cancer drugs highlights
- The Mexico breast cancer drugs generated a revenue of USD 112.1 million in 2023 and is expected to reach USD 181.8 million by 2030.
- The Mexico market is expected to grow at a CAGR of 7.1% from 2024 to 2030.
- In terms of segment, targeted therapy was the largest revenue generating therapy in 2023.
- Immunotherapy is the most lucrative therapy segment registering the fastest growth during the forecast period.
Breast cancer drugs data book summary
| Market revenue in 2023 | USD 112.1 million |
| Market revenue in 2030 | USD 181.8 million |
| Growth rate | 7.1% (CAGR from 2023 to 2030) |
| Largest segment | Targeted therapy |
| Fastest growing segment | Immunotherapy |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Chemotherapy, Immunotherapy, Targeted Therapy, Hormonal Therapy |
| Key market players worldwide | Novartis AG ADR, Pfizer Inc, Merck KGaA, Janssen Pharmaceuticals, Celgene, Roche Holding AG, AstraZeneca PLC, AbbVie Inc, Bristol-Myers Squibb Co, Macrogenics Inc, Celldex Therapeutics Inc, Sanofi SA, Amgen Inc |
Other key industry trends
- In terms of revenue, Mexico accounted for 1.3% of the global breast cancer drugs in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Latin America, Brazil breast cancer drugs is projected to lead the regional market in terms of revenue in 2030.
- Mexico is the fastest growing regional market in Latin America and is projected to reach USD 181.8 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Breast Cancer Drugs Scope
Breast Cancer Drugs Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Mexico breast cancer drugs outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to breast cancer drugs will help companies and investors design strategic landscapes.
Targeted therapy was the largest segment with a revenue share of 64.23% in 2023. Horizon Databook has segmented the Mexico breast cancer drugs based on chemotherapy, immunotherapy, targeted therapy, hormonal therapy covering the revenue growth of each sub-segment from 2018 to 2030.
Large geriatric population and increase in the burden of breast cancer in Mexico are likely to aid market growth. According to WHO, around 27,283 people were reported to be suffering from breast cancer in 2018, and approximately 6,884 people died due to it.
Various organizations in Mexico are striving to create awareness and educate patients about the benefits of early diagnosis & available treatment options. For instance, the Mexican Institute of Social Security (IMSS) launched the Mi lucha es rosa campaign in 2016 to increase awareness and enable prevention of breast cancer in the country.
Moreover, HIPGIVE is raising funds for a campaign—Keep a Breast Mexico—to support breast cancer research and educate the youth of Mexico. Increasing number of collaborations and R&D for discovery of cancer drugs is expected to drive the Mexican breast cancer drugs market over the forecast period.
Reasons to subscribe to Mexico breast cancer drugs databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Mexico breast cancer drugs databook
-
Our clientele includes a mix of breast cancer drugs companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Mexico breast cancer drugs, including forecasts for subscribers. This country databook contains high-level insights into Mexico breast cancer drugs from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Mexico breast cancer drugs market size, by therapy, 2018-2030 (US$M)
Mexico Breast Cancer Drugs Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
